Biogen's MS drug candidate performs well in Phase III study

04/25/2012 | Mass High Tech (Boston)

A second late-stage trial showed that Biogen Idec's oral drug candidate BG-12 significantly reduced relapse and additional brain lesions in patients with relapsing-remitting multiple sclerosis over two years compared with placebo. Glatiramer acetate was used as a reference comparator. BG-12 also demonstrated safety and tolerability.

View Full Article in:

Mass High Tech (Boston)

Published in Brief: